Letter to the Editor
Case of hypophysitis caused by nivolumab
Masashi Ishikawa,
Corresponding Author
Masashi Ishikawa
Department of Dermatology, Saitama Cancer Center, Saitama, Japan
Correspondence: Masashi Ishikawa, M.D., Department of Dermatology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama 362-0806, Japan. Email:
[email protected]Search for more papers by this author Kohei Oashi,
Kohei Oashi
Department of Dermatology, Saitama Cancer Center, Saitama, Japan
Search for more papers by this author
Masashi Ishikawa,
Corresponding Author
Masashi Ishikawa
Department of Dermatology, Saitama Cancer Center, Saitama, Japan
Correspondence: Masashi Ishikawa, M.D., Department of Dermatology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama 362-0806, Japan. Email:
[email protected]Search for more papers by this author Kohei Oashi,
Kohei Oashi
Department of Dermatology, Saitama Cancer Center, Saitama, Japan
Search for more papers by this author
First published: 14 May 2016
No abstract is available for this article.
References
- 1Topalian SL, Sznol M, McDermott DF et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol 2014; 32: 1020–1030.
- 2Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384.
- 3Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23–34.
- 4Faje AT, Sullivan R, Lawrence D et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99: 4078–4085.
- 5Albarel F, Gaudy C, Castinetti F et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015; 172: 195–204.